Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04957511 · ClinicalTrials.gov registry record
Gut Microbiome and Treatment for Gynecological Cancer Patients Receiving Immunotherapy
A clinical trial of Gynecologic Cancer and Gut Microbiome, sponsored by Viome.
- Recruiting
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT04957511: Recruiting study of Gynecologic Cancer and Gut Microbiome, sponsored by Viome.
NCT04957511 is a study of Gynecologic Cancer and Gut Microbiome that is actively recruiting participants, run by Viome. The registered enrollment target is 30 participants, below the 764-participant average among 55 other Gynecologic Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04957511, a study of Gynecologic Cancer and Gut Microbiome, is actively recruiting participants, sponsored by Viome.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
30 participants with advanced or recurrent gynecological cancer from are enrolled for this study. Eligible participants then provide fecal specimen, blood, vaginal swab, oral mucosal swab and receive food dietary recommendation. Additional samples are collected for results analysis.
Primary Outcome
Changes are measured between the genetic microbiome signatures of advanced or recurrent gynecological cancer patients who are receiving immune checkpoint inhibitors.
Conditions Studied
Study Locations (1)
Florida
- AdventHealth Cancer Institute - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-06-29 |
| Est. Completion | 2026-06 |
What NCT04957511 shows while recruiting
NCT04957511 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 764-participant average among 55 other Gynecologic Cancer trials with a reported enrollment target (96% lower).
The record links to 3 conditions, with Gynecologic Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT04957511 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT04957511 about?
NCT04957511 is a clinical study titled "Gut Microbiome and Treatment for Gynecological Cancer Patients Receiving Immunotherapy". 30 participants with advanced or recurrent gynecological cancer from are enrolled for this study. Eligible participants then provide fecal specimen, blood, vaginal swab, oral mucosal swab and receive food dietary recommendation. Additional samples are collected for results analysis.
What is the current status of trial NCT04957511?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2021-06-29. Estimated completion is 2026-06.
What conditions does trial NCT04957511 study?
This clinical trial studies the following conditions: Gynecologic Cancer, Gut Microbiome, Immunotherapy.
Who is sponsoring clinical trial NCT04957511?
This trial is sponsored by Viome, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04957511 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gynecologic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04957511's enrollment target sits among peer trials
30 43rd of 55 higher than 11 of 55 other Gynecologic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gynecologic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PROmOting Gynecologic Cancer Patients With Frailty to Achieve Functional Recovery
RECRUITING
-
Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors
RECRUITING · NA
-
Chatbot to Maximize Hereditary Cancer Genetic Risk Assessment
RECRUITING · NA
-
BOLSTER: Learning New Skills to Thrive
RECRUITING · NA
-
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
RECRUITING · NA
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI